JP7851625B2 - 宿主因子ｌｉｐｇをターゲットとした抗ｂ型肝炎ウイルス剤 - Google Patents

宿主因子ｌｉｐｇをターゲットとした抗ｂ型肝炎ウイルス剤

Info

Publication number
JP7851625B2
JP7851625B2 JP2023538494A JP2023538494A JP7851625B2 JP 7851625 B2 JP7851625 B2 JP 7851625B2 JP 2023538494 A JP2023538494 A JP 2023538494A JP 2023538494 A JP2023538494 A JP 2023538494A JP 7851625 B2 JP7851625 B2 JP 7851625B2
Authority
JP
Japan
Prior art keywords
sequence
polypeptide
lipg
hbv
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023538494A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023008337A5 (https=
JPWO2023008337A1 (https=
Inventor
弘志 柳川
典子 田畠
裕子 米村
真由子 井手
哲 伊藤
周一 金子
政夫 本多
尚芳 白崎
和寿 村居
光 岡田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purotech Bio Inc
Original Assignee
Purotech Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purotech Bio Inc filed Critical Purotech Bio Inc
Publication of JPWO2023008337A1 publication Critical patent/JPWO2023008337A1/ja
Publication of JPWO2023008337A5 publication Critical patent/JPWO2023008337A5/ja
Application granted granted Critical
Publication of JP7851625B2 publication Critical patent/JP7851625B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023538494A 2021-07-26 2022-07-22 宿主因子ｌｉｐｇをターゲットとした抗ｂ型肝炎ウイルス剤 Active JP7851625B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021121446 2021-07-26
JP2021121446 2021-07-26
PCT/JP2022/028503 WO2023008337A1 (ja) 2021-07-26 2022-07-22 宿主因子ｌｉｐｇをターゲットとした抗ｂ型肝炎ウイルス剤

Publications (3)

Publication Number Publication Date
JPWO2023008337A1 JPWO2023008337A1 (https=) 2023-02-02
JPWO2023008337A5 JPWO2023008337A5 (https=) 2024-10-22
JP7851625B2 true JP7851625B2 (ja) 2026-04-27

Family

ID=85086920

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023538494A Active JP7851625B2 (ja) 2021-07-26 2022-07-22 宿主因子ｌｉｐｇをターゲットとした抗ｂ型肝炎ウイルス剤

Country Status (4)

Country Link
US (1) US20240277861A1 (https=)
EP (1) EP4378480A1 (https=)
JP (1) JP7851625B2 (https=)
WO (1) WO2023008337A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023176861A1 (ja) * 2022-03-15 2023-09-21 ピューロテックバイオ株式会社 宿主因子ｄｅｎｎｄ２ａをターゲットとした抗ｂ型肝炎ウイルス剤

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002540127A (ja) 1999-03-26 2002-11-26 アベンティス ファーマスーティカルズ プロダクツ インコーポレイテッド コレステロールのレベルをもたらすための組成物および方法
JP2010539123A (ja) 2007-09-14 2010-12-16 エスシーアイエル テクノロジー ゲゼルシャフト ミット ベシュレンクテル ハフツング 変性疾患の処置のための神経内分泌因子
WO2017082202A1 (ja) 2015-11-09 2017-05-18 Ｉｄａｃセラノスティクス株式会社 抗ウイルス薬
WO2017132420A1 (en) 2016-01-26 2017-08-03 The Methodist Hospital Compositions and methods for suppression and diagnosis of cancer metastasis
WO2023090381A1 (ja) 2021-11-18 2023-05-25 ピューロテックバイオ株式会社 宿主因子ｄｏｃｋ１１をターゲットとした抗ｂ型肝炎ウイルス剤
WO2023176861A1 (ja) 2022-03-15 2023-09-21 ピューロテックバイオ株式会社 宿主因子ｄｅｎｎｄ２ａをターゲットとした抗ｂ型肝炎ウイルス剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003106675A1 (ja) 2002-06-12 2003-12-24 学校法人 慶應義塾 翻訳テンプレートおよびそのライブラリー、それらから合成される蛋白質および蛋白質のライブラリー、ならびにそれらを構成する要素、ならびにそれらの製造法および利用方法
EP3309178A4 (en) 2015-06-11 2019-05-08 Keio University FUSION PROTEIN OR CONJUGATED PROTEIN, CARRIER FOR INTRA-CELLULAR DELIVERY, PARTICLE PEPTIDE, CELL MEMBRANE PERMEATION AMPLIFIER, DNA AND VECTOR

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002540127A (ja) 1999-03-26 2002-11-26 アベンティス ファーマスーティカルズ プロダクツ インコーポレイテッド コレステロールのレベルをもたらすための組成物および方法
JP2010539123A (ja) 2007-09-14 2010-12-16 エスシーアイエル テクノロジー ゲゼルシャフト ミット ベシュレンクテル ハフツング 変性疾患の処置のための神経内分泌因子
WO2017082202A1 (ja) 2015-11-09 2017-05-18 Ｉｄａｃセラノスティクス株式会社 抗ウイルス薬
WO2017132420A1 (en) 2016-01-26 2017-08-03 The Methodist Hospital Compositions and methods for suppression and diagnosis of cancer metastasis
WO2023090381A1 (ja) 2021-11-18 2023-05-25 ピューロテックバイオ株式会社 宿主因子ｄｏｃｋ１１をターゲットとした抗ｂ型肝炎ウイルス剤
WO2023176861A1 (ja) 2022-03-15 2023-09-21 ピューロテックバイオ株式会社 宿主因子ｄｅｎｎｄ２ａをターゲットとした抗ｂ型肝炎ウイルス剤

Also Published As

Publication number Publication date
US20240277861A1 (en) 2024-08-22
EP4378480A1 (en) 2024-06-05
WO2023008337A1 (ja) 2023-02-02
JPWO2023008337A1 (https=) 2023-02-02

Similar Documents

Publication Publication Date Title
US12331290B2 (en) Recombinant nucleic acid molecule and application thereof in preparation of circular RNA
US12466884B2 (en) Tissue-specific WNT signal enhancing molecules and uses
Liang et al. TRIM26 is a critical host factor for HCV replication and contributes to host tropism
US20080089862A1 (en) Protease inhibitors and method of screening thereof
US20240182538A1 (en) Modulation of ifi16 and sting activity
Yang et al. Inhibition of hepatitis C virus infection by DNA aptamer against envelope protein
WO2010058819A1 (ja) ヒト癌タンパク質ＭＤＭ２とヒト癌抑制タンパク質ｐ５３との相互作用阻害ペプチド及びその使用
US8623363B2 (en) Anti-HCV monoclonal antibody as a medicament for the therapeutic treatment and prevention of HCV infections
JP7851625B2 (ja) 宿主因子ｌｉｐｇをターゲットとした抗ｂ型肝炎ウイルス剤
WO2023090381A1 (ja) 宿主因子ｄｏｃｋ１１をターゲットとした抗ｂ型肝炎ウイルス剤
CN105734059A (zh) Gp73抑制剂及其用途
US20220089695A1 (en) Targeting SARS-CoV-2 Viral-immune Interaction for COVID-19 Therapy
JP5794514B2 (ja) 腫瘍血管新生阻害剤
Fan et al. Coronavirus S protein alters dsRNA accumulation and stress granule formation through regulation of ADAR1-p150 expression
EP3992205A1 (en) Sars coronavirus-2 spike protein binding compounds
WO2023176861A1 (ja) 宿主因子ｄｅｎｎｄ２ａをターゲットとした抗ｂ型肝炎ウイルス剤
Song et al. LRRC15 is an inhibitory receptor blocking SARS-CoV-2 spike-mediated entry in trans
JP6986263B2 (ja) 抗ウイルス薬
US20160200804A1 (en) Compositions and methods for treating anaplastic thyroid cancer
EP4223878A1 (en) Sars-cov-2-binding peptide
WO2004087762A1 (ja) ペプチドトランスポーターの輸送活性を阻害する抗体
CN116615460A (zh) β-血影蛋白(SPTBN1)缺乏保护小鼠免于高脂肪饮食诱导的肝病和癌症发展
EP4553160A1 (en) Antiviral agent, pharmaceutical composition for treating or preventing viral infection, kit for evaluating risk of viral infection becoming severe, and method for evaluating risk of viral infection becoming severe
JP5669271B2 (ja) 腫瘍血管新生阻害剤
US20140072567A1 (en) Methods Of Treating And Preventing Glucose Toxicity

Legal Events

Date Code Title Description
AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20240408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260401

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260408

R150 Certificate of patent or registration of utility model

Ref document number: 7851625

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150